Evolus Inc
NASDAQ:EOLS

Watchlist Manager
Evolus Inc Logo
Evolus Inc
NASDAQ:EOLS
Watchlist
Price: 5.69 USD 0.53%
Market Cap: 368.8m USD

Net Margin
Evolus Inc

-20.5%
Current
-32%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-20.5%
=
Net Income
-58.6m
/
Revenue
285.8m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Evolus Inc
NASDAQ:EOLS
366.6m USD
-20%
US
Eli Lilly and Co
NYSE:LLY
1.1T USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
500.7B USD
27%
CH
Roche Holding AG
SIX:ROG
269.6B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
221.5B GBP
16%
CH
Novartis AG
SIX:NOVN
219.5B CHF
26%
US
Merck & Co Inc
NYSE:MRK
277.7B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
33%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
-126%
US
Pfizer Inc
NYSE:PFE
144.7B USD
16%
No Stocks Found

Evolus Inc
Glance View

Market Cap
368.5m USD
Industry
Pharmaceuticals

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 167 full-time employees. The company went IPO on 2018-02-08. The Company’s first commercial product is Jeuveau, which is an approximately 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. The company offers customers and consumers a compelling value proposition with Jeuveau. BOTOX (onabotulinumtoxinA) is also an approximately 900 kDa botulinum toxin type A complex approved in the United States.

EOLS Intrinsic Value
23.56 USD
Undervaluation 76%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-20.5%
=
Net Income
-58.6m
/
Revenue
285.8m
What is the Net Margin of Evolus Inc?

Based on Evolus Inc's most recent financial statements, the company has Net Margin of -20.5%.

Back to Top